Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or
Continue Reading Emerging Companies: Framework for Leveraging Your IP & Tech
Dan Shores is a partner at Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has served companies utilizing the following technologies (without limitation): mRNA; lipid nanoparticles; CAR-T; oligonucleotides; genetically engineered swine organs for xenotransplantation; artificial intelligence for drug discovery; small molecules; biologics, materials science, and numerous other technologies throughout his 20-year career. Dan has a B.S. in engineering with a specialization in materials science from the University of New Hampshire and a J.D. from the Georgetown University Law Center. He is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.
Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or…
Continue Reading Emerging Companies: Framework for Leveraging Your IP & Tech
Quick heads up, the World Economic Forum released a Special Report covering what it considers to the the top 10…
Continue Reading World Economic Forum Releases Top 10 Emerging Technologies of 2020
As Pfizer and BioNTech announced this week that results of their COVID-19 vaccine have exceeded expectations, the technology behind the…
Continue Reading Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It?
This week, Ryder System, Inc. (NYSE: R), announced a new corporate venture capital fund called RyderVentures.
The fund seeks to…
Continue Reading Ryder Launches $50M Venture Fund for Supply Chain Startups
Founders routinely need to disclose their groundbreaking technologies to third party investors, suitors, collaborators, peers, consultants and others in order…
Continue Reading Key Considerations Regarding Early Disclosures and Patent Protection
Pharmaceutical giant Eli Lilly and Company will purchase four-year-old Disarm Therapeutics, a Cambridge-based biotechnology company, for $135 million up…
Continue Reading Eli Lilly to Buy Disarm Therapeutics for $135M Plus Potentially $1B+
Researchers at the University of Cambridge have developed software that produces super-resolution virtual, 3D images of cells contained in actual…
Continue Reading University of Cambridge Develops Virtual Reality Software to Help Explore Cells
Boston-based Moderna has announced that it will not enforce its patent rights related to its experimental vaccine for COVID-19, because…
Continue Reading Moderna Reportedly Won’t Enforce its COVID-19 Vaccine Patents
French microLED display startup Aledia announced it closed an €80M first tranche of its €120M D-round financing. The company will…
Continue Reading Aledia, French microLED Startup, Announces €80M First Tranche Close on €120M Round
Leaders of emerging companies must make many critical decisions at the outset of their company’s growth cycle, not the least…
Continue Reading Critical Steps for Building Winning Patent Portfolios
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.